CSP Pharmacoeconomics & Reimbursement 2

Question 1

Specialty drug A costs $60,000 more than drug B and yields 1.5 additional QALYs. What is the ICER of A versus B?

Accepted Answer

$40,000 per QALY

Answer

ICER = incremental cost / incremental effect = $60,000 / 1.5 QALYs = $40,000 per QALY.

Question 2

Two biosimilar products have demonstrated equivalent efficacy and safety. Which pharmacoeconomic analysis is most appropriate to choose between them?

Accepted Answer

Cost-minimization analysis

Answer

When outcomes are proven equivalent, only costs need comparison, so cost-minimization analysis applies.

Question 3

A health system values both the costs of a hepatitis C program and the avoided liver transplants in dollars. Which analysis is this?

Accepted Answer

Cost-benefit analysis

Answer

Cost-benefit analysis expresses both inputs and outcomes in monetary units, allowing a net benefit or benefit-to-cost ratio.

Question 4

A new therapy is both less costly and more effective than the current standard. How is it described on the cost-effectiveness plane?

Accepted Answer

Dominant

Answer

An option that costs less and produces better outcomes dominates the comparator, so no ICER needs calculating.

Question 5

A 10-year model of a gene therapy reduces the present value of future costs and health outcomes, commonly at 3% per year. What is this practice called?

Accepted Answer

Discounting

Answer

Discounting reflects time preference by converting future costs and outcomes to present value, typically at about 3% annually in US analyses.

CSP - Certified Specialty Pharmacist Practice Test

CSP - Certified Specialty Pharmacist Practice Test

CSP Pharmacoeconomics & Reimbursement 2